By inhibiting FGFR1, Erdafitinib reduces FGF23 levels, which diminishes the inhibition of sodium-phosphate co-transporters in renal proximal tubules, thereby increasing renal phosphate reabsorption and resulting in hyperphosphatemia (Kommalapati et al., 2021). The gene discussed is FGF23; the disease is hyperphosphatemia.